Innovotech Inc. (TSXV: IOT, OTCQB: IOTCF) announced that its common shares have commenced trading on the OTCQB Market in the United States under the symbol IOTCF, while continuing to trade on the TSX Venture Exchange under IOT. The listing aims to enhance engagement with U.S. investors as the company builds a larger, more diversified life sciences platform.
CEO Craig Milne stated, "Listing on the OTCQB allows us to more effectively engage with U.S. investors as we build a larger, more diversified life sciences platform." The company recently reported strong operational progress and financial performance in 2025, including a significant increase in revenues driven by organic growth and the full-year contribution from the acquisition of Keystone Labs Inc. in November 2024. Innovotech delivered consistent revenues across all quarters, reflecting improved scale, operational execution, and a more diversified revenue base.
During 2025, Innovotech successfully integrated Keystone, expanding its analytical chemistry and testing capabilities and strengthening its Canadian customer base. After year-end, the company completed the amalgamation of its operating entities, simplifying its corporate structure into a single, integrated laboratory platform. The company also strengthened its balance sheet through warrant exercises and a convertible debenture issuance, providing capital for equipment purchases, operational expansion, and strategic initiatives. Investments in laboratory infrastructure removed capacity bottlenecks and expanded technical capabilities with advanced analytical and microbiology equipment.
Innovotech’s differentiation lies in its expertise in antimicrobial testing and biofilm-related research, supported by accredited quality systems and the ability to execute complex, custom testing programs. The company is frequently engaged on technically challenging projects requiring reproducibility, regulatory awareness, and close collaboration with client development teams, resulting in long-standing customer relationships and higher-value contract research. Beyond services, Innovotech manufactures and sells laboratory consumables, including its MBEC Assay® platform, used globally in biofilm and antimicrobial research. The company also maintains an active R&D program focused on expanding assay offerings and advancing proprietary technologies, such as its InnovoSIL™ antimicrobial silver platform.
Looking ahead to 2026, Innovotech is focused on continued organic growth, expansion of service offerings, and disciplined execution of strategic priorities. The company is actively evaluating acquisition opportunities and continuing to invest in infrastructure, people, and systems to support scale. Following its OTCQB listing, Innovotech is expanding investor outreach efforts in the United States. Dr. Milne added, "We are building Innovotech deliberately. Our focus is on long-term value creation through operational excellence, differentiated capabilities, and disciplined growth. We look forward to introducing Innovotech to a broader U.S. investor audience and sharing our progress as we continue to execute."
Innovotech Inc. is an established and scaling life sciences services and technology company specializing in contract research, analytical, and microbial testing within regulated healthcare markets. The company is a recognized leader in biofilm science and antimicrobial testing and provides advanced laboratory services supporting medical device, pharmaceutical, and industrial product development. Operating through ISO-certified and GMP-accredited laboratories, Innovotech supports clients across multiple sectors and geographies, delivering reliable, decision-enabling data aligned with regulatory expectations such as those of the U.S. Food and Drug Administration and Health Canada. More information is available at https://www.innovotech.ca.
